Development and Implementation of Pharmacist-based Diabetic Intervention Model in type-2 diabetes patients in Pakistan: A randomized controlled trial
Not Applicable
Active, not recruiting
- Conditions
- Diabetes mellitusMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12619001618145
- Lead Sponsor
- Tauqeer Hussain
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Type-2 diabetes mellitus
Exclusion Criteria
Pregnancy
Juvenile Type Diabetes
Type-1 diabetes
Dementia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1C<br>by Serum assay[180 days];Medication adherence by Morisky Medication Adherence Scale (MMAS)[180 days];Health Related Quality of Life<br>by Euro Qol EQ-5D-5L[180 days]
- Secondary Outcome Measures
Name Time Method Blood pressure<br>by using automated machine[180 days];Lipid Profile (Triglycerides, cholesterol, HDL, LDL)<br>by serum assay[180 days];Body Fats<br>by using Fat analyzer machine[180 days];BMI<br>by using fat analyzer machine (Omron Fat analyzer Model: BF508)<br>A stadiometer will used to assess height in centimeters.[180 days]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by pharmacist-led diabetes interventions in ACTRN12619001618145 for type-2 diabetes in Pakistan?
How does pharmacist-based intervention compare to standard-of-care in reducing HbA1c for type-2 diabetes in Pakistan?
Which biomarkers predict response to pharmacist-led diabetes management in low-resource type-2 diabetes populations?
What adverse events are associated with pharmacist-managed diabetes interventions and their management strategies in ACTRN12619001618145?
What drug classes or combination therapies are optimized through pharmacist-led models for type-2 diabetes in Pakistan?